The role of neuromodulation in patients with neurogenic overactive bladder

Current Urology Reports

Volumn 13, Issue 5, 2012, Pages 343-347

  Lay, Aaron H ^a   Das, Anurag K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Lower urinary tract dysfunction; Multiple sclerosis; Neurogenic overactive bladder; Sacral nerve; Sacral neuromodulation

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

BLADDER CATHETERIZATION; BLADDER SURGERY; BLURRED VISION; COGNITIVE DEFECT; CONSTIPATION; DETRUSOR MUSCLE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMITTENT CATHETERIZATION; LIFESTYLE MODIFICATION; MEMORY DISORDER; MINIMALLY INVASIVE PROCEDURE; NEUROGENIC OVERACTIVE BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; PELVIC FLOOR MUSCLE TRAINING; REVIEW; SACRAL NERVE STIMULATION; TREATMENT RESPONSE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXINS; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; HUMANS; LUMBOSACRAL PLEXUS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 84869205360     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0272-y     Document Type: Review

References (31)

1. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol. 1989; 142: 340-5. (Pubitemid 19197110)
2. Van Kerrebroeck PE, Marcelissen TA. Sacral neuromodulation for lower urinary tract dysfunction. World J Urol. 2011.
3. Thompson JH, Sutherland SE, Siegel SW. Sacral neuromodulation: therapy evolution. Indian J Urol. 2010; 26(3): 379-84.
4. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167-78. (Pubitemid 34195211)
5. Aizenberg D, Sigler M, et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4 year case control study. Int Psychogeriatr. 2002; 14: 307-10. (Pubitemid 35375545)
6. Kumar SPV, Abrams PH. Detrusor myectomy: long-termresults with a minimum follow-up of 2 years. BJU International. 2005; 96: 341-4. (Pubitemid 41097679)
7. Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord. 1997; 35: 456-62. (Pubitemid 27316466)
8. Stohrer M, Kramer G, Goepel M, et al. Bladder auto-augmentation in adult neurogenic bladder: long term follow-up. J Urol. 2000; 163: 224A.
9. Hasan ST, Marshall C, Robson WA, Neal DE. Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol. 1995; 76: 551-7. (Pubitemid 26029688)
10. Erbguth FJ. Historical notes on botulism, clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004; 19: S2-6. (Pubitemid 38967505)
11. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986; 26: 427-53. (Pubitemid 16090969)
12. Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: State of the art. Rev Urol. 2006; 8: 198-208.
13. Schurch B, de seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6- month study. J Urol. 2005; 174(1): 196-200. (Pubitemid 40825713)
14. Herschorn S, Gajewski J, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011; 185(6): 2229-35. This is a prospective, double-blind, placebo-controlled, randomized trial which demonstrated Botox is efficacious and safe in patients with neurogenic detrusor overactivity and urinary incontinence. Clinical benefit was seen for up to 9 months.
15. Cruz F, Herschorn S, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011; 60(4): 742-50. This is a prospective, double-blind, placebo-controlled, randomized trial which demonstrated Botox is efficacious and safe in patients with neurogenic detrusor overactivity and urinary incontinence. Botox reduced incontinence episodes and improved QOL in MS and SCI patients with NDO. The median time to request for re-treatment was 42 weeks.
16. Hassouna MM, Siegel SW, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000; 163(6): 1849-54. (Pubitemid 30366751)
17. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000; 56: 87-91.
18. Bosch JL, Groen J. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. J Urol. 2000; 163: 1219-22. (Pubitemid 30169397)
19. Dasgupta R, Wiseman OJ, Kitchen N, et al. Long-term results of sacral neuromodulation for women with urinary retention. BJU Int. 2004; 94: 335-7. (Pubitemid 39120175)
20. Sutherland SE, Lavers A, Carlson A, et al. Sacral nerve stimulation for voiding dysfunction: one institution's 11-year experience. Neurourol Urodyn. 2007; 26: 19-28. (Pubitemid 46175442)
21. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007; 178: 2029-34. (Pubitemid 47554439)
22. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence: sacral nerve stimulation study group. J Urol. 1999; 162: 352-7. (Pubitemid 29434339)
23. Weil EH, Ruiz-Cerda JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000; 37: 161-71. (Pubitemid 30103068)
24. Vasdev N, Biles BD, Sandher R, Hasan TS. The surgicalmanagement of the refractory overactive bladder. Indian J Urol. 2010; 26: 263-9.
25. Roguin A, Zviman MM, et al. Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: in vitro and in vivo assessment of safety and function at 1.5 T. Circulation. 2004; 110(5): 475-82. (Pubitemid 39031161)
26. Martin ET. Can cardiac pacemakers and magnetic resonance systems coexist? Eur Heart J. 2005; 26: 325-7. (Pubitemid 40283090)
27. Gimbel K, Gimbel JR, Kanal E. Can patients with implantable pacemakers safely undergo magnetic resonance imaging? J Am Coll Cardiol. 2004; 43: 1325-7. (Pubitemid 38452613)
28. Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010; 58(6): 865-74. This is a review and meta-analysis of studies that assessed the efficacy and safety of SNM use in patients with neurogenic lower urinary tract dysfunction.
29. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007; 197(1): 96e1-5.
30. Sahai A, Cortes E, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011; 12(6): 404-12.
31. Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010; 67(1): 74-84. This is a case series of 10 patients with complete spinal cord lesions who underwent early bilateral SNM implantation demonstrating promising results.